Can Enbrel (etanercept) or Plaquenil (hydroxychloroquine) cause bruising?

Can Enbrel or Plaquenil Cause Bruising?

Yes, both Enbrel (etanercept) and Plaquenil (hydroxychloroquine) can cause bruising, though through different mechanisms and with different frequencies.

Enbrel (Etanercept) and Bruising

Enbrel carries a clear FDA warning about bruising as a sign of potentially serious hematologic complications 1. The drug label explicitly instructs patients to "seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor)" 1.

Mechanism and Severity

Enbrel can cause rare but serious blood disorders including:

• Pancytopenia (affecting all blood cell lines)
• Aplastic anemia (some fatal cases reported)
• Thrombocytopenia (low platelets leading to bruising/bleeding)

The FDA label notes these occur in <0.1% of patients, with aplastic anemia being even rarer at <0.01% 1. However, case reports document these complications occurring even after a single dose 2.

Clinical Presentation

When bruising occurs with Enbrel, it may manifest as:

• Injection site reactions with erythema, edema, and bruising that typically resolve within 2-3 days 3
• Purpuric rash at injection sites associated with drug-induced thrombocytopenia 4
• Petechial rash with systemic pancytopenia 2

Critical pitfall: Bruising with Enbrel should never be dismissed as a simple injection site reaction. Any persistent or widespread bruising warrants immediate CBC evaluation to rule out serious cytopenia 1.

Monitoring Requirements

Guidelines recommend 5, 6:

• Baseline CBC before starting therapy
• Periodic CBC monitoring during treatment (consider yearly)
• Immediate evaluation if bruising, bleeding, or pallor develops

Plaquenil (Hydroxychloroquine) and Bruising

Hydroxychloroquine-induced pigmentation preceded by ecchymosis (bruising) is a well-documented adverse effect 7. A case-control study found that 92% of patients with HCQ-induced pigmentation reported that pigmented lesions were preceded by ecchymotic areas 7.

Mechanism

The bruising associated with Plaquenil appears to result from:

• Increased susceptibility to ecchymosis in patients with predisposing factors
• Conversion of bruised areas to persistent blue-gray or brown pigmentation due to iron deposition in skin 7

This is distinct from hematologic toxicity—the bruising reflects local vascular fragility rather than systemic coagulation defects.

Risk Factors

HCQ-induced pigmentation with preceding bruising is independently associated with 7:

• Concurrent anticoagulant or antiplatelet therapy (strongest association)
• Higher blood HCQ concentrations
• Longer treatment duration (median 6.1 years, but can occur as early as 3 months)

96% of affected patients had at least one condition predisposing to easy bruising 7.

Clinical Significance

Unlike Enbrel, the bruising with Plaquenil:

• Does not typically indicate serious hematologic toxicity
• Represents a cosmetic concern that may progress to permanent pigmentation
• Should prompt evaluation of concurrent medications that increase bleeding risk

Practical Management Algorithm

If bruising develops on Enbrel:

1. Obtain immediate CBC with differential and platelet count
2. If cytopenias confirmed → discontinue Enbrel immediately 1
3. If CBC normal and bruising limited to injection sites → may continue with close monitoring
4. Consider switching to alternative biologic if injection site reactions are problematic

If bruising develops on Plaquenil:

1. Review concurrent anticoagulants/antiplatelets—consider dose adjustment or alternatives
2. Check blood HCQ level if available
3. Counsel patient about potential for persistent pigmentation
4. Document bruising pattern and monitor for progression
5. No need to discontinue unless other concerning features develop

The key distinction: Bruising with Enbrel may herald life-threatening bone marrow suppression requiring immediate drug cessation, while bruising with Plaquenil typically represents a benign but potentially permanent cosmetic issue related to medication interactions or drug accumulation.